Otros

<p>Applications 7-Ethyl-5-oxo-5H-[1]benzopyrano[2,3-b]pyridine is known to show antihistiminic and anaphylactic compounds. Maintains potential anti-inflammatory compounds.<br>References Valhondo, M. et al.: J. Med. Chem., 56, 7851 (2013); Ozcan, S. et al.: J. Med. Chem., 56, 3783 (2013); Tozzi, S. et al.: J. Med. Chem., 18, 1 (1975);<br></p>

<p>Applications Gimeracil is an antitumor agent. Gimeracil is a potent inhibitor of dihydropyrimidine dehydrogenase (DPD).<br>References Shirasaka, T., et al.: Cancer Res., 56, 2602 (1996), Patt, Y., et al.: J. Clin. Oncol., 22, 271 (2004), Shirao, K., et al.: Cancer, 100, 2355 (2004), Kelly, H., et al.: J. Clin. Oncol., 23, 4553 (2005),<br></p>

<p>Applications Labelled MDV 3100. MDV 3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer.<br>References Scher, H.I. et al.: Lancet, 375, 1437 (2010); Bellmunt, J. et al.: Ther. Adv. Med. Oncol., 2, 189 (2010); Ryan, C.J. et al.: J. Clin. Oncol., 29, 3651 (2011);<br></p>

<p>Applications Zaleplon Formide is an impurity of Zaleplon (Z145000), a selective non-benzodiazepine GABAA receptor agonist.<br>References Radl, S., et al.: J. Heterocycl. Chem, 47, 276 (2010); Allen, D., et al.: Eur. J. Clin. Pharmacol., 45, 313 (1993); Beer, B., et al.: J. Clin. Pharmacol., 34, 335 (1994); Rosen, A.S., et al.: Biopharm. Drug Dispos., 20, 171 (1999)<br></p>

<p>Applications Selective non-benzodiazepine GABAA receptor agonist.<br>References Allen, D., et al.: Eur. J. Clin. Pharmacol., 45, 313 (1993), Beer, B., et al.: J. Clin. Pharmacol., 34, 335 (1994), Rosen, A.S., et al.: Biopharm. Drug Dispos., 20, 171 (1999), Elie, R., et al.: J. Clin. Psychiatry, 60, 536 (1999), Heydorn, W.E., et al.: Expert Opin. Invest. Drugs, 9, 841 (2000)<br></p>

<p>Stability Light Sensitive<br>Applications Bimatoprost is an antiglaucoma agent. Bimatoprost is an synthetic prostamide; structurally related to prostaglandin F2α.<br>References Brandt, J.D., et al.: Ophthalmology, 108, 1023 (2001), Woodward, D.F., et al.: J. Pharmacol. Exp. Ther., 305, 772 (2003), Quinones, R., et al.: J. Ocul. Pharmacol. Ther., 20, 115 (2004),<br></p>

<p>Stability Hygroscopic<br>Applications Used as an antiparkinsonian and antispasmodic.<br>References Rohde, H., et al.: Fortschr. Med., 100, 2023 (1982), Kornhuber, J., et al.: Eur. J. Pharmacol., 166, 589 (1989), Gortelmeyer, R. and Erbler, H.: Arzneimittel-Forsch., 42, 904 (1992)<br></p>

<p>Applications MDV 3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer.<br>References Scher, H.I. et al.: Lancet, 375, 1437 (2010); Bellmunt, J. et al.: Ther. Adv. Med. Oncol., 2, 189 (2010); Ryan, C.J. et al.: J. Clin. Oncol., 29, 3651 (2011);<br></p>

<p>Stability Hygroscopic<br>Applications Cyclopyrrolone member of a family of non-benzodiazepine GABAA receptor agonists. This is a controlled substance (depressant) in the US but not in Canada. Sedative, hypnotic.<br>References Noble, S., et al.: Drugs, 55, 277 (1998), Musch, B., et al.: Int. J. Clin. Psychopharmacol., 5, 147 (1990),<br></p>

<p>Applications Labelled Bimatoprost (B386800). Bimatoprost is an antiglaucoma agent. Bimatoprost is an synthetic prostamide; structurally related to prostaglandin F2α.<br>References Brandt, J.D., et al.: Ophthalmology, 108, 1023 (2001), Woodward, D.F., et al.: J. Pharmacol. Exp. Ther., 305, 772 (2003), Quinones, R., et al.: J. Ocul. Pharmacol. Ther., 20, 115 (2004),<br></p>

<p>Applications Silodosin is an α1a-adrenoceptor antagonist. It is used in treatment of benign prostatic hypertrophy.<br>References (1) Shibata, K., et al.: Mol. Pharmacol., 48, 250 (1995) (2) Murata, S., et al.: J. Urol., 164, 578 (2000)<br></p>